(FILE 'HOME' ENTERED AT 14:51:45 ON 14 JUN 2007)

```
FILE 'MEDLINE, CAPLUS, BIOSIS, PCTFULL' ENTERED AT 14:52:00 ON 14 JUN 2007
L1
          40428 S OSTEOCLAST
L2
        5038229 S INHIBIT?
          15434 S L1 (L) L2
L3
L4
           5098 S L3 AND GENE
L5
            498 S L4 AND MICROARRAY
             71 S L5 AND PY<2002
L6
        1130293 S FOLD
L7
             44 S L6 (L) L7
\Gamma8
             44 DUP REM L8 (0 DUPLICATES REMOVED)
L9
L10
             44 S L9 AND TREATMENT
             13 S L10 AND (BONE (1S) RESORP?)
L11
                E STASHENKO PHILIP /AU
            303 S E1-5
L12
                E SASKI HAJIME /AU
L13
              8 S E2
                E BATTAGLINO RICHARD /AU
L14
             13 S E1-2
                E SPAETE ULRIKE /AU
L15
              9 S E2-3
L16
            319 S L12-15
             24 S L16 AND OSTEOCLAST AND INHIB?
L17
            12 DUP REM L17 (12 DUPLICATES REMOVED)
L18
```

WUCHERPFENNIG, Anne, L.

- L18 ANSWER 9 OF 12 MEDLINE on STN DUPLICATE 6
- TI Pathogenesis of induced rat periapical lesions.
- PY 1994

1 . . .

- AU Stashenko P; Wang C Y; Tani-Ishii N; Yu S M
- L18 ANSWER 10 OF 12 MEDLINE on STN DUPLICATE 7
- TI Platelet activating factor increases intracellular calcium in isolated osteoclasts but does not modify bone resorption.
- PY 1993
- AU Wucherpfennig A L; Dewhirst F E; Stashenko P
- L18 ANSWER 11 OF 12 MEDLINE ON STN DUPLICATE 8
- TI Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo.
- PY 1991
- AU Nguyen L; Dewhirst F E; Hauschka P V; Stashenko P
- L18 ANSWER 12 OF 12 MEDLINE on STN DUPLICATE 9
- TI Interleukin-1 beta is a potent inhibitor of bone formation in vitro.
- PY 1987
- AU Stashenko P; Dewhirst F E; Rooney M L; Desjardins L A; Heeley J D

ANSWER 1 OF 12 MEDLINE on STN DUPLICATE 1 L18 Fluoxetine treatment increases trabecular bone formation in mice. ΤI PY 2007 ΑU Battaglino R; Vokes M; Schulze-Spate U; Sharma A; Graves D; Kohler T; Muller R; Yoganathan S; Stashenko P ANSWER 2 OF 12 MEDLINE on STN · DUPLICATE 2 L1.8 Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. PY Keles Ahmet; Grunes Brandon; Difuria Catherine; Gagari Eleni; Srinivasan ΑU Vasanth; Darendeliler Mehmet A; Muller Ralph; Kent Ralph Jr; Stashenko Philip ANSWER 3 OF 12 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN L18 PSTPIP1 silencing by si RNA alters osteoclast morphology and TIincreases resorption in vitro. PY Battaglino, R. A. [Reprint Author]; Spaete, U.; Morse, L. R.; ΑU Pham, L.; Stashenko, P. ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3 L18 Nucleic acid and polypeptide markers for osteoclasts and their TIdiagnostic and therapeutic uses involving bone resorption and bone mineral density PY 2004 2007 2004 2005 2006 Stashenko, Philip; Okamatsu, Yoshimura; Sasaki, Hajime; ΙN Battaglino, Ricardo; Spaete, Ulrike MEDLINE on STN DUPLICATE 4 ANSWER 5 OF 12 L18 Serotonin regulates osteoclast differentiation through its TΙ transporter. PΥ 2004 Battaglino Ricardo; Fu Jia; Spate Ulrike; Ersoy Ulku; Joe ΑU Martha; Sedaghat Leela; Stashenko Philip COPYRIGHT 2007 Univentio on STN L18 ANSWER 6 OF 12 PCTFULL METHODS FOR INCREASING BONE DENSITY TIEN TIFR PROCEDE PERMETTANT D'ACCROITRE LA DENSITE OSSEUSE STASHENKO, Philip, 10 Newport Lane, Medfield, MA 02053, US [US, ΙN US]; BATTAGLINO, Ricardo, 75 Saint Alphonsus Street, Boston, MA 02120, US [AR, US] L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5 Protein and cDNA sequences of human a novel protein RGS10B, a G-protein regulator expressed in osteoclasts, and uses thereof in drug screening and diagnosis PΥ 2001 2001 2002 2003 Stashenko, Philip; Li, Yi-Ping ΙN COPYRIGHT 2007 Univentio on STN ANSWER 8 OF 12 L18 PCTFULL HUMAN OSTEOCLAST-SPECIFIC AND -RELATED GENES TIEN GENES HUMAINS SPECIFIQUES ET APPARENTES AUX OSTEOCLASTES TIFR STASHENKO, Philip; ΤN LI, Yi-Ping;